non-small cell lung cancer

The BIRAC funding will enable comprehensive toxicology assessments, a critical step in preparing for IND submission with…

Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is…

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by…

Earlier this year, Pfizer acquired ADC giant Seagen for $43 billion in one of the largest M&A deals in industry history

Docetaxcel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric…

The approval for AstraZeneca molecule is based on the findings of TOPAZ-1, a Phase-3 global clinical trial with patients recruited…

Erlotinib Tablets are indicated for the treatment of patients with metastatic non-small cell lung cancer and locally advanced,…

It is now approved as monotherapy for adjuvant treatment after complete tumour resection in patients with NSCLC

Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung…

The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer